Does Insurance Cover Wegovy for Teens?

Some plans cover Wegovy for patients 12 and older, and many do not. Nearly all that do require prior authorization. The most common reason for denial is not the child — it is that the plan excludes weight-management medications entirely as a benefit design choice, regardless of medical need.

This is the part of the process that surprises families most. You can do everything right, meet the FDA criteria, document a year of effort, get a specialist's support, and still be denied because of a line in your employer's benefits contract written before anyone knew your child existed.

Knowing which kind of obstacle you are facing determines whether it is worth appealing.

First: does your plan cover weight-management drugs at all?

Before any clinical question, answer this administrative one. It changes everything downstream.

Many employer-sponsored plans carry a blanket exclusion for anti-obesity medications. If yours does, no amount of documentation will produce an approval through the standard pathway, because the plan is not saying your child fails to qualify — it is saying the category is not a covered benefit.

How to find out in one phone call. Call the member services number on the back of the card and ask three questions:

1. Does this plan cover anti-obesity or weight-management medications at all?
2. Is Wegovy on the formulary, and at which tier?
3. What are the prior authorization criteria for a patient under 18?

Ask for the reference number for the call. You will want it later.

What prior authorization typically requires

Criteria vary by insurer and by individual plan, and self-funded employer plans can set their own rules entirely. That said, requests for adolescents commonly ask for:

• Age 12 or older. This matches the FDA indication and is rarely negotiable.
• BMI at or above the 95th percentile for age and sex, documented in the chart. This is the FDA's criterion for the adolescent indication.
• Documented lifestyle intervention. Many plans want evidence of a structured attempt over a period of months — visit notes, nutrition counseling, activity documentation. Verbal advice recorded as "counseled on diet" is frequently rejected.
• Weight-related conditions, where relevant. Insulin resistance, prediabetes, fatty liver, hypertension, dyslipidemia, obstructive sleep apnea, PMOS.
• Step therapy, on some plans. A documented trial of a preferred or lower-cost alternative first.
• Prescriber requirements. Some plans require the prescription come from, or be co-signed by, a specialist.

Renewals typically require evidence the medication is working. A commonly used benchmark is a defined percentage of weight reduction within the initial approval window. Approval periods are often six or twelve months.

Why claims get denied

In rough order of frequency:

The plan excludes the drug class. Not a clinical judgment. See above.

Documentation is thin. The single most fixable reason. The plan needs to see the BMI percentile in the chart, the dates and content of the lifestyle intervention, and the comorbidities named explicitly with supporting labs. A request that asserts these without documenting them gets denied.

Step therapy was not completed. The plan required a trial of something else first, and that trial is not in the record.

The wrong product was requested. A request for a medication with no pediatric indication for the child's age will be denied on those grounds. Ozempic is not a workaround here — it has no pediatric approval for any use, which we explain in Ozempic vs Wegovy for teens.

Age. Below 12, there is no approved indication to authorize against.

Administrative error. Wrong form, missing signature, expired authorization, submitted to the wrong benefit. More common than families assume, and worth ruling out before mounting a clinical appeal.

What to do after a denial

A first denial is not the end of the process. It is frequently the middle of it.

Get the reason in writing. The denial letter must state the specific basis. "Not medically necessary" is not specific enough — ask which criterion was not met.

Match the appeal to the reason. A documentation denial needs records, not argument. A step therapy denial needs either the trial or a documented reason the alternative is inappropriate. A plan exclusion needs a different strategy entirely — usually a formulary exception request or an appeal grounded in a covered comorbidity.

Ask about a peer-to-peer review. Your physician can request a direct conversation with the plan's medical director. These are often more productive than written appeals, because a specialist can explain the specific clinical picture in a way a checklist cannot capture.

Know your external review rights. If internal appeals are exhausted, most plans are subject to independent external review. The denial letter is required to explain how to request one.

Ask about the manufacturer's savings program. Eligibility rules apply and vary, but it is worth checking while an appeal is pending.

What a pediatric endocrinologist adds to the process

Some of this is clinical and some is clerical, and the clerical part is what families most often lack support with.

Documentation that matches what plans look for. BMI percentile recorded correctly, comorbidities named with supporting labs, the lifestyle intervention described with dates and specifics rather than summarized.

The growth history that makes the case. For a metabolic evaluation at LIFE we collect both the first five years and the last five years of height and weight data. A twelve-year trajectory showing weight crossing percentile lines is far more persuasive to a reviewer than a single BMI value, and it is often the difference in an appeal.

Identification of comorbidities that change the calculus. Insulin resistance, fatty liver, sleep apnea, and PMOS are frequently present and undiagnosed. Finding them is good medicine first. It also strengthens a request substantially.

Confirmation that the medication is even the right question. Sometimes the workup reveals a thyroid problem, a medication side effect, or a genetic cause of obesity — in which case the treatment plan changes and the Wegovy appeal becomes irrelevant.

Someone to conduct the peer-to-peer. This is where a specialist's involvement is hardest to substitute.

A separate pattern worth knowing: if your child's weight is rising while height growth has slowed, that combination points toward an endocrine cause and deserves evaluation regardless of any medication question. We cover it in weight up, height stalled.

What this looks like at LIFE

Families are never required to enroll in a program to be seen. You can come in specifically for a metabolic evaluation, for help with an appeal already in progress, or for a second opinion on a medication that has been recommended elsewhere.

We are a concierge practice and do not bill insurance for visits. Prescriptions we write can still be submitted to your pharmacy benefit, and we prepare the documentation to support that.

Frequently asked questions

Does insurance cover Wegovy for teens?

Some plans do and many do not. Wegovy is FDA-approved from age 12, but coverage is a separate question from approval, and a large number of employer plans exclude weight-management medications as a category. Nearly every plan that does cover it requires prior authorization before the prescription will be filled.

What is required for Wegovy prior authorization for a teenager?

Plans commonly require the patient to be 12 or older with a documented BMI at or above the 95th percentile for age and sex, plus records of a structured lifestyle intervention over several months. Some also require documented weight-related conditions, a trial of a preferred alternative first, or a specialist prescriber.

Why was my teen's Wegovy claim denied?

The most common reason is that the plan excludes weight-management medications entirely, which is a benefit design decision rather than a clinical judgment. Other frequent reasons include insufficient documentation of BMI percentile or lifestyle intervention, incomplete step therapy, the patient being under 12, or an administrative error.

Can a pediatric endocrinologist help with prior authorization?

Yes. A specialist can document the BMI percentile and full growth trajectory, identify and record weight-related conditions with supporting labs, describe the lifestyle intervention in the detail plans require, and request a peer-to-peer review with the plan's medical director. That last step is often the most effective part of an appeal.

Medically reviewed by

Natalie Hernandez, MD — Pediatric endocrinologist and lead physician for metabolic and obesity medicine at LIFE. Board certified in Pediatrics; board eligible in Pediatric Endocrinology. Fellowship at Duke University Hospital with research on insulin resistance and youth-onset type 2 diabetes. Full profile →

Toni Kim, MD — Founder, LIFE Pediatric Endocrinology. Board-certified pediatric endocrinologist. Full profile →

Talk with a pediatric endocrinologist

If you are in the middle of an appeal, or trying to work out whether a denial is worth fighting, that is a reasonable thing to bring to a specialist.

LIFE Pediatric Endocrinology sees families nationwide by telemedicine, and in person at our offices in Austin, Sandy Springs, Beverly Hills, Newport Beach, and Brentwood. Request a consultation →

Medical disclaimer

This article is for general educational purposes and does not constitute medical advice. It is not a substitute for evaluation, diagnosis, or treatment by a qualified healthcare professional, and reading it does not create a physician-patient relationship. Coverage rules vary by plan and change over time; verify details with your insurer. Every child is different. Do not start, stop, or change any medication based on this article. Talk with your child's pediatrician or a pediatric endocrinologist about your child's specific situation. If your child has a medical emergency, call 911 or go to the nearest emergency department.

Sources

• U.S. Food and Drug Administration — Wegovy (semaglutide) prescribing information
• Hampl SE, et al. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents with Obesity. Pediatrics. 2023.
• Centers for Medicare & Medicaid Services — external review and appeal rights under the Affordable Care Act